Nicollet Investment Management Inc. Has $599,000 Stock Position in Solventum Co. (NYSE:SOLV)

Nicollet Investment Management Inc. lessened its holdings in Solventum Co. (NYSE:SOLV) by 4.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,064 shares of the company’s stock after selling 457 shares during the period. Nicollet Investment Management Inc.’s holdings in Solventum were worth $599,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Modus Advisors LLC purchased a new stake in shares of Solventum in the fourth quarter valued at about $25,000. Stonebridge Financial Group LLC purchased a new stake in Solventum in the 4th quarter valued at about $26,000. True Wealth Design LLC lifted its position in shares of Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after buying an additional 471 shares in the last quarter. Crews Bank & Trust purchased a new position in shares of Solventum in the 4th quarter worth approximately $32,000. Finally, Synergy Asset Management LLC bought a new position in shares of Solventum in the fourth quarter valued at approximately $35,000.

Solventum Stock Performance

Shares of SOLV opened at $76.02 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock has a market capitalization of $13.15 billion and a price-to-earnings ratio of 27.64. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The stock’s 50-day simple moving average is $75.56 and its 200 day simple moving average is $71.92.

Analysts Set New Price Targets

A number of brokerages have issued reports on SOLV. Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Mizuho upped their price objective on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Morgan Stanley raised their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Wells Fargo & Company increased their price target on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, The Goldman Sachs Group boosted their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.